Queensland scientists begin human testing today for 'molecular clamp' Covid-19 vaccine

Henrietta Strickland
July 13, 2020

It comes as the first human trials for a COVID-19 vaccine are set to get underway in Queensland tomorrow.

There are at least 21 vaccines now under key trials, according to the World Health Organisation (WHO). The first group will be permitted to leave in two-three days and the second group will be discharged on July 20.

15 volunteers have already been given the trial vaccines and testing is expected to ramp up to include as many as 200-300 new participants in the coming weeks. "It corresponds to the safety of those vaccines that are now on the market", the new agency quoted Lukashev as saying.

"We have great scientists in Queensland and they are doing a remarkable job so we wish them all the very best as they undertake these trials", she said.

The coronavirus vaccine was developed by Russia's Ministry of Defence in collaboration with Moscow's Gamalei Institute of Epidemiology and Microbiology.

Tarasov noted that Sechenov University has emerged as a scientific and technological research centre for this vaccination rather than just acting as an educational institution at a time when countries are reeling under the pressure from the novel Coronavirus transmission.

On Wednesday, the French government said it was preparing for a second wave of Covid-19, but rather than imposing another nationwide lockdown, they would use "targeted" measures such as stay-at-home orders or business closures. And, is a vector vaccine based on adenovirus DNA, in which the SARS-CoV-2 coronavirus gene is integrated.

Stanford and Harvard university-educated Kirill Dmitriev, CEO of Russian Direct Investment Fund (RDIF), commented: "The Russian research base for vaccine development is one of the best globally, and we expect that the Russian vaccine will be one of the first in the world ready to be used", reported TrialSiteNews.

While many news reports claimed this woul be the first vaccine to complete human trials, the time-frame and objective of the research suggest that it has only cleared-or is still ongoing-phase 1 of trials.

In addition, a June 22 report published by Sputnik News quoted Gamaleya's director, Alexander Gintsburg, as saying that the vaccine would protect people against the virus for a period of over two years.

Other reports by Click Lancashire

Discuss This Article